SARS-CoV-2 Leading Vaccine Candidates: Progress and Development
Abstract
The coronavirus disease 2019 (COVID-19) outbreak that originated in China in December 2019, spread globally and was declared a public health emergency of international concern by WHO. The genome sequence of novel coronavirus (SARS-CoV-2) was made available publicly in an unprecedented time that allowed rapid research and development to combat this deadly virus. Due to the absence of therapeutics, vaccines could be a promising solution towards the control and prevention of SARS-CoV-2 infections. As a quick response to this pandemic, the already established vaccine platforms are being explored for development of an effective vaccine against SARS-CoV-2. Thus, the clinical trials to evaluate the safety and efficacy of experimental vaccines are emerging in a record time. In this review various vaccine strategies that include nucleic acid (mRNA and DNA), viral vector based, partial or complete genome based inactivated, and protein subunit vaccines are summarized. We have also highlighted the status of clinical trials currently in progress and the preliminary findings of these frontrunner vaccine candidates. To eradicate the current COVID-19 pandemic and to prevent future outbreaks, successful vaccine platforms should be capable of scalable manufacturing and global distribution.
References
Coronavirus Disease (COVID-2019) Situation Reports 177; World Health Organization, 2020. https://www.who.int/emergencies/diseases/novel- coronavirus-2019/situation-reports.
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536-44.
Wu F, Zhao S,Yu B, Chen Y, Wang W, Song Z, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579: 265-9.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565–74.
Wu A, Peng Y, Huang B, Ding, X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020; 27: 325–8.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367: 1260–3.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire T, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181: 281–92.
Draft landscape of COVID-19 candidate vaccines. August 13, 2020. World Health Organization. https://www.who.int/publications/m/item/draft- landscape-of-covid-19-candidate-vaccines
Bull JJ, Nuismer SL, Antia R. Recombinant vector vaccine evolution, PLoS Comput Biol. 2019; 15: 1006857.
Ura T, Okuda K, Shimada M. Developments in Viral Vector- Based Vaccines. Vaccines. 2014; 2: 624-41.
van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 30: 1-8.
Mullard A. COVID-19 vaccines start moving into advanced trials. Nat Rev Drug Discov. 2020; 19: 435.
Oxford COVID-19 Vaccine Trials. Oxford's ChAdOx1 nCoV-19 clinical trials [press release]. July 19, 2020. https://www.research.ox.ac.uk/Article/2020-07-19- oxford-covid-19-vaccine-trials.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij- Rammerstorfer S. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396: 467-78.
Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE. 2012; 7: e40385
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose- escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395: 1845-54.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo- controlled, phase 2 trial. Lancet. 2020; 396: 479-88.
Johnson & Johnson Announces Acceleration of its COVID- 19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July. June 10, 2020. https://www.jnj.com/ johnson-johnson-announces-acceleration-of-its-covid-19- vaccine-candidate-phase-1-2a-clinical-trial-to-begin-in- second-half-of-july.
Johnson & Johnson. Latest Facts About Johnson & Johnson's Investigational COVID-19 Vaccine. July 20, 2020. https://www.jnj.com/latest-news/latest-facts-news- about-johnson-johnson-covid-19-vaccine-candidate.
Callaway E. Russia's fast-track coronavirus vaccine draws outrage over safety. Nature. 2020; 584: 334-5.
Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016; 41: 18–22.
Kramps T, Elbers K. Introduction to RNA vaccines. Methods Mol Biol. 2017; 1499: 1–11.
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109: 14604–9.
Atkins G, Fleeton M, Sheahan B. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev
Mol Med. 2008; 10: e33.
Iavarone C, Derek TO, Dong Y, Nicolas F, Delahaye, Jeffrey BU. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017; 16: 871-81.
Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020; 395: 1751 – 1752.
Maruggi G, Zhang C, Li J, Ulmer JB, Yu Dong. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019; 27: 757 – 772. 28. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020.
Edward EW, Robert F, Ann RF, Nicholas K, Judith A, Alejandra G, et al. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. 2020.
Mark JM, Kirsten EL, Nicholas K, Judith A, Alejandra G, Stephen L, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. 2020.
Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020.
GaoQ,BaoL,MaoH,WangL,XuK,YangM,etal.Rapid development of an inactivated vaccine candidate for SARS- CoV-2. Science. 2020
Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11: 2601.
David Ho, Gina Lee. South Korea's Genexine begins phase I/IIa trials for COVID-19 vaccine. Bio World. 2020. https://www.bioworld.com/articles/435995-south- koreas-genexine-begins-phase-iiia-trials-for-covid-19- vaccine.
Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. Chem Med Chem. 2013; 8: 360–76.
Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine [press release]. August 24, 2020. https://ir.novavax.com/news-releases/news-release- details/novavax-initiates-phase-2-portion-phase-12- clinical-trial-covid.
Novavax Reports Second Quarter 2020 Financial and Operational Results [press release]. August 10, 2020. https://ir.novavax.com/news-releases/news-release- details/novavax-reports-second-quarter-2020-financial- and-operational.
Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega- Rivera OA, et al. COVID-19 vaccine development and a potential nano material path forward. Nat Nanotechnol. 2020; 15: 646-55.
